Yungjin Pharm Co Ltd Cash Flow Reinvestment Rate
Yungjin Pharm Co Ltd cash flow reinvestment rate. Yungjin Pharm Co Ltd (003520) has a Cash Flow Reinvestment Rate of 0.61x as of September 2025, reinvesting ₩4.28 Billion (capex ₩2.16 Billion plus investments ₩-2.12 Billion) from operating cash flow of ₩7.00 Billion. Explore Yungjin Pharm Co Ltd cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Yungjin Pharm Co Ltd (2013–2024)
Cash flow reinvestment rate of Yungjin Pharm Co Ltd from 2013 to 2024. Historical reinvestment intensity for Yungjin Pharm Co Ltd across 10 annual periods. Explore Yungjin Pharm Co Ltd (003520) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.
Yungjin Pharm Co Ltd Cash Flow Reinvestment Rate by Year (2013–2024)
Yungjin Pharm Co Ltd cash flow reinvestment rate by year from 2013 to 2024. Year-by-year capital reinvestment analysis for Yungjin Pharm Co Ltd. For the full cash flow conversion analysis, see 003520 cash flow conversion.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.13x | ₩24.61 Billion | ₩21.74 Billion | ₩21.61 Billion | ▼ -19.9% |
| 2021 | 1.41x | ₩11.82 Billion | ₩8.37 Billion | ₩11.32 Billion | ▲ +71.3% |
| 2020 | 0.82x | ₩11.96 Billion | ₩14.50 Billion | ₩6.30 Billion | ▼ -63.0% |
| 2019 | 2.23x | ₩20.69 Billion | ₩9.28 Billion | ₩10.36 Billion | ▼ -61.3% |
| 2018 | 5.76x | ₩7.34 Billion | ₩1.27 Billion | ₩4.71 Billion | ▲ +9.4% |
| 2017 | 5.26x | ₩16.59 Billion | ₩3.15 Billion | ₩10.59 Billion | ▲ +240.9% |
| 2016 | 1.54x | ₩4.81 Billion | ₩3.11 Billion | ₩4.69 Billion | ▼ -10.4% |
| 2015 | 1.72x | ₩15.16 Billion | ₩8.80 Billion | ₩13.75 Billion | ▼ -6.1% |
| 2014 | 1.84x | ₩11.41 Billion | ₩6.22 Billion | ₩11.30 Billion | ▲ +38.1% |
| 2013 | 1.33x | ₩7.91 Billion | ₩5.95 Billion | ₩6.63 Billion | — |